ENG/中
老虎證券
市场
行情
24/7新闻
产品
Cash Boost账户
期权
A股通
港股
固定票息票据
美股
ETF
基金超市
美国国债
新加坡股
期货
Tiger BOSS Debit Card
老虎钱袋子
功能
经纪人
定投
CPF/SRS 投资
专栏
美股碎股
TigerAI
费用
综合账户
股票与ETF
期权、窝轮与牛熊证
期货
债券
基金超市
Cash Boost
股票与ETF
融资利率
活动
帮助
账户操作
如何开户
开户文件
账户类型
资金与转仓
入金
DDA快捷入金
出金
转入股票
转出股票
货币兑换
产品与交易
可交易产品
订单类型
交易规则
申报
融资融券
保证金与杠杆
风险管理
做空风险
基金超市
基金开户与交易
Cash Boost账户
Cash Boost 账户FAQ
如何开通 Cash Boost 账户
如何用Cash Boost 账户交易
如何绑定CDP证券账户
Tiger Boss Debit Card
常见问题
费用说明
如何充值
如何使用我的Debit card
账单报表
账单报表
股息(分红)
机构
Tiger Fund Management
机构服务
财富及资产管理人
自营交易机构
介绍经纪商
三方服务商
老虎API平台
登入
立即註冊
Toggle
澳股
詳情
本頁面由Tiger Trade Technology Pte. Ltd.提供服務
新冠治療股
968.611
+8.935
0.93%
漲家數:
8
跌家數:
9
平家數:
16
市盈率:
- -
高:
970.918
開:
960.287
低:
960.287
收:
959.676
成交量:
1,970.98萬
成交額:
2.85億
市值:
2,388.75億
流通市值:
1,958.82億
資料載入中...
總覽
新聞資訊
Woolworths:5月1日至8月1日,300款凍結價格商品從未出現標價上漲
美股速递
·
09/11
Woolworths否認《澳洲衞報》關於2026年5月1日至8月1日三個月價格凍結的報道
美股速递
·
09/11
瑞思邁(RMD)股票9月8日盤中下跌3.15%:背後推手曝光
TradingKey中文
·
09/09
BCAL診斷公司:要求罷免Michael Aicher,並提名Forrester與Melki進入GSS董事會
美股速递
·
09/03
遺傳特徵公司要求BCAL診斷澄清其在GSS的持股及關聯方詳情
美股速递
·
09/03
瑞思邁(RMD)股票9月1日盤中下跌3.25%:釋放什麼信號?
TradingKey中文
·
09/02
英國監管機構因數據不可靠,暫停安進公司Tavneos用於新患者
路透中文
·
09/01
CSL重大擴產計劃:大幅提升免疫球蛋白及白蛋白生產能力,惠及罕見病與重症患者
美股速递
·
09/01
CSL達成協議:為美國藥品定價及特定232條款關税風險增添確定性
美股速递
·
09/01
CSL有限公司:項目預計創造至少300個製藥製造業新崗位及約800個建築及相關崗位
美股速递
·
09/01
CSL與美國政府達成協議 降價藥品並助力本土製造投資
美股速递
·
09/01
CSL有限公司:新協議助力降低療法價格,彰顯15億美元擴建伊利諾伊州美國產能計劃
美股速递
·
09/01
特朗普政府將宣佈藥品定價協議
路透中文
·
09/01
{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股,新股,港股,A股等全球金融理财产品。新加坡华人最信赖的在线投资平台,现在加入即享低费用,24/5 无时差炒美股投资理财!","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股,新股,港股,A股等全球金融理财产品。新加坡华人最信赖的在线投资平台,现在加入即享低费用,24/5 无时差炒美股投资理财!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.etasphere.com/hant/stock/BK7501/news"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BK7501","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK7501\",,,,,undefined,":{"symbol":"BK7501","market":"AU","secType":"PLATE","nameCN":"新冠治療股","latestPrice":968.6111,"timestamp":1789451999873,"preClose":959.6761,"halted":0,"volume":19709778,"delay":0,"changeRate":0.00931,"floatShares":0,"shares":0,"eps":0,"marketStatus":"未開盤","change":8.934998,"latestTime":"09-15 16:00:00 AEST","open":960.2871,"high":970.9179,"low":960.2871,"amount":285223474,"amplitude":0.011077,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"開盤","tradingStatus":0,"beginTime":1789516800000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"openAndCloseTimeList":[[1789430400000,1789452000000]],"turnoverRate":0.001376,"increases":10,"decrements":7,"flats":15,"marketCap":238874544673.25,"floatMarketCap":195881654934.0547},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK7501\",,,,,undefined,":{"symbol":"BK7501","high":970.9179,"amplitude":0.011077,"preClose":959.6761,"low":960.2871,"latestPrice":968.6111,"volume":19709778,"delay":0,"open":960.2871,"prevYearClose":900.1661,"prevWeekClose":945.016,"prevMonthClose":977.169,"prevQuarterClose":826.677,"fiveDayClose":968.269,"twentyDayClose":927.145,"sixtyDayClose":804.086,"secType":"PLATE","market":"AU","turnoverRate":0.001376,"marketCap":238874544673.25,"floatMarketCap":195881654934.0547,"timestamp":1789451999873,"nameCN":"新冠治療股"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK7501\",,,,undefined,":{"bkCode":"BK7501","up":8,"down":9,"flat":16},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK7501\",pageSize:20,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1143113007","title":"Woolworths:5月1日至8月1日,300款凍結價格商品從未出現標價上漲","url":"https://stock-news.laohu8.com/highlight/detail?id=1143113007","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1143113007?lang=zh_tw&edition=fundamental","pubTime":"2026-09-11 13:15","pubTimestamp":1789103710,"startTime":"0","endTime":"0","summary":"Woolworths 明确表示,从5月1日到8月1日期间,其所实施的300款商品价格冻结计划中,没有任何一款商品的售价曾超过其货架标价。这家零售巨头强调,在整个价格冻结时段内,所有入选产品的货架价格均保持稳定,未出现任何上调情况。据该公司透露,这一举措旨在为消费者提供确定性,并缓解生活成本压力。Woolworths 进一步指出,尽管外部市场环境存在波动,但其承诺始终如一——即确保消费者在结账时支付的价格不高于货架标签所示价格。这一声明回应了外界对价格冻结计划执行情况的关注,同时彰显了其在通胀压力下对顾客透明度的重视。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7511","WOW.AU","BK7040","BK7501"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1128362521","title":"Woolworths否認《澳洲衞報》關於2026年5月1日至8月1日三個月價格凍結的報道","url":"https://stock-news.laohu8.com/highlight/detail?id=1128362521","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1128362521?lang=zh_tw&edition=fundamental","pubTime":"2026-09-11 13:14","pubTimestamp":1789103648,"startTime":"0","endTime":"0","summary":"Woolworths——坚决否认《澳洲卫报》所刊发的有关其在2026年5月1日至8月1日期间实施为期三个月价格冻结的报道。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["WOW.AU","BK7501","BK7511","BK7040"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666211371","title":"瑞思邁(RMD)股票9月8日盤中下跌3.15%:背後推手曝光","url":"https://stock-news.laohu8.com/highlight/detail?id=2666211371","media":"TradingKey中文","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666211371?lang=zh_tw&edition=fundamental","pubTime":"2026-09-09 00:16","pubTimestamp":1788884175,"startTime":"0","endTime":"0","summary":"• 瑞思迈因Astral呼吸机暂停相关费用及利润率压力而面临抛售压力。\n• 市场对GLP-1类药物的担忧以及飞利浦可能重返市场,继续抑制着该板块的情绪。\n• 瑞思迈完成了对MatrixCare的剥离,为加速股票回购和提高股息提供了资金。","market":"fut","thumbnail":"https://resource.tradingkey.com/cms_uploads/img/20230814/292a73ea96beb98e5f665e124a82e00c.jpg","type":0,"news_type":0,"thumbnails":["https://resource.tradingkey.com/cms_uploads/img/20230814/292a73ea96beb98e5f665e124a82e00c.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tradingkey.com/zh-hans/news/market-movers/262156449-market-movers-rmd-20260908","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","LGHT","BK4504","RMD.AU","BK7007","LU2177674079.SGD","IE00B5TLWC47.USD","LU0170899867.USD","BK4585","BK4548","LU2008162690.USD","RMD","BK7501","BK4082","BK4567"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1173556031","title":"BCAL診斷公司:要求罷免Michael Aicher,並提名Forrester與Melki進入GSS董事會","url":"https://stock-news.laohu8.com/highlight/detail?id=1173556031","media":"美股速递","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1173556031?lang=zh_tw&edition=fundamental","pubTime":"2026-09-03 10:42","pubTimestamp":1788403333,"startTime":"0","endTime":"0","summary":"BCAL诊断有限公司已正式提出动议,要求将Michael Aicher从Genetic Signatures Ltd董事会中罢免。与此同时,该公司还力荐Forrester及Melki两位候选人,以期他们能够顺利加入GSS董事会。这一人事调整举措,无疑为GSS公司的治理结构投下了一枚重磅炸弹。BCAL方面显然希望通过此番运作,重塑董事会的权力格局,注入新鲜血液。BCAL此举的深层动因,以及新任董事若顺利上位后将带来怎样的治理新风,均有待市场的进一步观察与解读。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","BDX.AU","BK7501","GSS.AU","BK7048"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1115211142","title":"遺傳特徵公司要求BCAL診斷澄清其在GSS的持股及關聯方詳情","url":"https://stock-news.laohu8.com/highlight/detail?id=1115211142","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1115211142?lang=zh_tw&edition=fundamental","pubTime":"2026-09-03 07:39","pubTimestamp":1788392350,"startTime":"0","endTime":"0","summary":"遗传特征有限公司(Genetic Signatures Ltd, GSS.AU)已正式向BCAL诊断有限公司(BCAL Diagnostics Ltd, BDX.AU)发出请求,要求后者就其在该公司的持股情况以及关联方关系提供更为详尽的说明。\n据悉,此项请求涉及BCAL诊断在遗传特征公司中的股东身份及相关联方细节,但具体交易背景及可能引发的后续影响尚未对外披露。市场参与人士正密切关注事态发展,以评估这一动向可能对两家澳大利亚医疗诊断领域企业带来的潜在影响。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7048","BK7501","GSS.AU","BK7067","BDX.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664852863","title":"瑞思邁(RMD)股票9月1日盤中下跌3.25%:釋放什麼信號?","url":"https://stock-news.laohu8.com/highlight/detail?id=2664852863","media":"TradingKey中文","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664852863?lang=zh_tw&edition=fundamental","pubTime":"2026-09-02 01:16","pubTimestamp":1788282992,"startTime":"0","endTime":"0","summary":"• 瑞思迈因 Astral 呼吸机暂停销售和战略产品组合调整而面临波动。\n• 管理层表示,尽管围绕 GLP-1 疗法的讨论仍在持续,但睡眠呼吸暂停市场的渗透率依然较低。\n• 该公司全年营收达到 56.5 亿美元,净利润达 15.2 亿美元。","market":"sh","thumbnail":"https://resource.tradingkey.com/cms_uploads/img/20230814/292a73ea96beb98e5f665e124a82e00c.jpg","type":0,"news_type":0,"thumbnails":["https://resource.tradingkey.com/cms_uploads/img/20230814/292a73ea96beb98e5f665e124a82e00c.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tradingkey.com/zh-hans/news/market-movers/262144537-market-movers-rmd-20260901","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4082","LU2177674079.SGD","BK4585","BK7007","BK4504","BK4567","BK4548","LU2008162690.USD","LU0170899867.USD","RMD","IE00B5TLWC47.USD","RMD.AU","BK7501","BK4588","LGHT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664347855","title":"英國監管機構因數據不可靠,暫停安進公司Tavneos用於新患者","url":"https://stock-news.laohu8.com/highlight/detail?id=2664347855","media":"路透中文","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664347855?lang=zh_tw&edition=fundamental","pubTime":"2026-09-01 19:15","pubTimestamp":1788261324,"startTime":"0","endTime":"0","summary":"英国监管机构因数据不可靠,暂停安进公司Tavneos用于新患者路透9月1日-英国药品监管机构周二暂停了安进公司旗下AMGN.O研发的罕见病药物Tavneos对新患者的使用和销售,称支持该药获批的主要研究结果不可靠。监管机构表示,由于主要临床试验的数据不可靠,该研究已无法证明该药有效,也无法证明其益处大于风险。Tavneos由ChemoCentryx公司研发,安进公司于2022年以37亿美元收购了该公司。欧洲委员会于8月撤销了Tavneos的批准,此前监管机构发现其关键试验数据不可靠。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260901:nL4T44T10B:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE0009355771.USD","IE00B4R5TH58.HKD","LU0058720904.USD","LU0889565916.HKD","LU2242646821.SGD","IE0002141913.USD","LU0868494617.USD","BK4581","LU1571399168.USD","LU2089984988.USD","BK7508","IBBQ","LU2112291526.USD","BK4139","IE00BJT1NW94.SGD","LU1023059063.AUD","IBB","LU1983299246.USD","LU0289739699.SGD","LU0122379950.USD","TBXU","SG9999001440.SGD","BK4588","LU1061106388.HKD","CSL.AU","IE00B2B36J28.USD","PBE","BK4533","IE00BJJMRZ35.SGD","BK7067","LU2242652126.USD","LU2468319806.SGD","BK7511","AMGN","BIB","IE00BFTCPJ56.SGD","PJP","LU1057294990.SGD","BBH","LU0320765992.SGD","BK7501","LU0109394709.USD","BK4534","BK4585","BK4566","BK4599"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1160995524","title":"CSL重大擴產計劃:大幅提升免疫球蛋白及白蛋白生產能力,惠及罕見病與重症患者","url":"https://stock-news.laohu8.com/highlight/detail?id=1160995524","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1160995524?lang=zh_tw&edition=fundamental","pubTime":"2026-09-01 03:27","pubTimestamp":1788204431,"startTime":"0","endTime":"0","summary":"CSL宣布了一项重大扩建项目,此举将显著增强其为罕见疾病及严重病症患者生产免疫球蛋白和白蛋白的能力。这一战略性举措不仅标志着公司在生物制药领域迈出的坚实一步,更意味着全球更多患者有望获得这些关键性治疗药物。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","BK7508","BK7501","CSL.AU","BK7511"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1181327820","title":"CSL達成協議:為美國藥品定價及特定232條款關税風險增添確定性","url":"https://stock-news.laohu8.com/highlight/detail?id=1181327820","media":"美股速递","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1181327820?lang=zh_tw&edition=fundamental","pubTime":"2026-09-01 03:25","pubTimestamp":1788204309,"startTime":"0","endTime":"0","summary":"CSL宣布,已通过相关协议为其在美国药品定价及部分第232条款关税方面的潜在风险敞口提供了更多确定性。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7508","BK7501","BK7067","BK7511","CSL.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1194972911","title":"CSL有限公司:項目預計創造至少300個製藥製造業新崗位及約800個建築及相關崗位","url":"https://stock-news.laohu8.com/highlight/detail?id=1194972911","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1194972911?lang=zh_tw&edition=fundamental","pubTime":"2026-09-01 03:24","pubTimestamp":1788204248,"startTime":"0","endTime":"0","summary":"CSL有限公司宣布,其新项目将带来显著的就业增长。据估计,该项目将直接催生至少300个制药制造领域的全新工作岗位。与此同时,建筑业及相关配套行业也将迎来约800个就业机会。这一系列的岗位创造计划,无疑将为当地经济注入新的活力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7501","BK7508","BK7511","BK7067","CSL.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1100124360","title":"CSL與美國政府達成協議 降價藥品並助力本土製造投資","url":"https://stock-news.laohu8.com/highlight/detail?id=1100124360","media":"美股速递","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1100124360?lang=zh_tw&edition=fundamental","pubTime":"2026-09-01 03:23","pubTimestamp":1788204189,"startTime":"0","endTime":"0","summary":"生物技术巨头CSL已与美国政府签署新协议,旨在降低部分药品价格,同时加大对美国本土生产设施的投资力度。此举被视为制药行业响应政府控价压力、巩固供应链安全的最新动向之一。根据协议内容,该公司将在积极推进制造业扩张的同时,向市场提供更具竞争力的定价。业界分析指出,这一安排既反映了企业在政策环境下的策略调整,也凸显了医疗健康领域对成本控制与产能韧性的双重诉求。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7501","BK7508","BK7511","CSL.AU","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1171032857","title":"CSL有限公司:新協議助力降低療法價格,彰顯15億美元擴建伊利諾伊州美國產能計劃","url":"https://stock-news.laohu8.com/highlight/detail?id=1171032857","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1171032857?lang=zh_tw&edition=fundamental","pubTime":"2026-09-01 03:23","pubTimestamp":1788204189,"startTime":"0","endTime":"0","summary":"CSL有限公司宣布,一系列新达成的协议将支持其疗法产品价格的进一步下调,并充分体现了该公司斥资15亿美元用于扩建其位于伊利诺伊州的美国生产基地的宏伟蓝图。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7501","CSL.AU","BK7511","BK7067","BK7508"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664002674","title":"特朗普政府將宣佈藥品定價協議","url":"https://stock-news.laohu8.com/highlight/detail?id=2664002674","media":"路透中文","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664002674?lang=zh_tw&edition=fundamental","pubTime":"2026-09-01 00:07","pubTimestamp":1788192474,"startTime":"0","endTime":"0","summary":"特朗普政府将宣布药品定价协议预计拜耳、武田、CSL以及中型生物技术公司将达成新协议路透此前曾报导,小型制药商认为参与其中的财务激励有限美国处方药价格往往是其他发达国家的近三倍路透8月31日-白宫一名官员表示,美国总统唐纳德·特朗普 预计将于周一宣布新一轮药品定价协议,这是旨在降低美国民众医疗保健成本举措的一部分。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260831:nL4T44S1CU:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0006306889.USD","LU1868837136.USD","LU2750360641.GBP","THNR","OZEM","IBBQ","BK7508","LU2361044949.HKD","GB00BDT5M118.USD","LU2746668974.SGD","MEDI","SG9999013999.USD","IE00B2B36J28.USD","LU0198837287.USD","SGXZ99366536.SGD","BK4139","ILDR","SG9999014880.SGD","LU0432979614.USD","LU0320765059.SGD","LU0385154629.USD","LU1035775433.USD","LU2417539215.USD","SG9999001176.USD","IXJ","LU2471134796.USD","LU1066051498.USD","IE00BJJMRY28.SGD","LU0170899867.USD","LU2462591350.SGD","LU0079474960.USD","LU2089984988.USD","LU0320765992.SGD","SG9999015978.USD","LU0266013472.USD","LU0225283273.USD","BK4516","LU1691799644.USD","LU2361044865.SGD","LU2552382058.USD","LU1548497426.USD","LU1061106388.HKD","LU2360106947.USD","LU0353189763.USD","LU1291159041.SGD","LU2265009873.SGD","SG9999014906.USD","LU1720051017.SGD","LLYZ","LU2028103732.USD","LU2168564222.USD","IE0002141913.USD","LU1868836757.USD","LU2213496289.HKD","LU0823434583.USD","LU1868836914.USD","CURE","IE00B1XK9C88.USD","LU2746668461.USD","LU0787776722.HKD","LU1145028129.USD","LU0210536198.USD","LU0203202063.USD","LU0256863811.USD","LU2324357040.USD","LU2552382132.HKD","SG9999011175.SGD","BK4581","LLYX","LU1093756168.USD","IE00B4JS1V06.HKD","LU2023250504.SGD","LU1983299246.USD","LLII","BK4533","IE0004445015.USD","LU1093756325.SGD","LU2236285917.USD","LU2602419157.SGD","LU0106261372.USD","LU2106854487.HKD","IE0002270589.USD","LU1023059063.AUD","LU0353189680.USD","SG9999014914.USD","BK7511","LU1989771016.USD","LU0097036916.USD","BK4566","LU0689472784.USD","LU1069344957.HKD","LU0708995401.HKD","LU1571399168.USD","LU1883839398.USD","IE000M9KFDE8.USD","LU0820561909.HKD","SG9999002232.USD","LU0672654240.SGD","IE00B7KXQ091.USD","LU0466842654.USD","LU0234572021.USD","CANC","IE0004445239.USD","IE00B4R5TH58.HKD","LU2063271972.USD","LU0225771236.USD","LU2111349929.HKD","CSL.AU","LU0786609619.USD","SG9999001440.SGD","SG9999015945.SGD","PJP","SGXZ57979304.SGD","IE00BJJMRX11.SGD","SG9999003800.SGD","IE00BFSS8Q28.SGD","LU2023250330.USD","LU2471134952.CNY","RXL","BK7501","LU0882574139.USD","LU1280957306.USD","LU1814569148.SGD","LU0417517546.SGD","IE00B3T34201.USD","FHLC","ELIS","LU0471298777.SGD","PBE","IE00BJT1NW94.SGD","SG9999017495.SGD","LU0061475181.USD","SG9999015952.SGD","LU0133085943.USD","LU2112291526.USD","TMED","SG9999015986.USD","IE00BLSP4239.USD","BBH","LU1064131342.USD","LU1868837300.USD","LU2168563687.JPY","BK4599","BK4550","LU0158827948.USD","LU1712237335.SGD","MHIP","LU0889565916.HKD","LU2896262040.SGD","04332","IE00BWXC8680.SGD","IE00BJJMRZ35.SGD","LU0321505868.SGD","LU2168564065.EUR","LU2468319806.SGD","LU0868494617.USD","LU2491049909.HKD","IONS","IE00BBT3K403.USD","LU0203201768.USD","LU2089284900.SGD","LU0323591593.USD","SG9999001176.SGD","LU1366192091.USD","LU2237438978.USD","BK4585","LU2271345857.HKD","LU2756315664.SGD","IE0009355771.USD","SG9999018865.SGD","LU0321505439.SGD","LU0820561818.USD","LU1057294990.SGD","IYH","LU2242646821.SGD","BK4568","LU2456880835.USD","LU0964807845.USD","LU1974910355.USD","LU0823416689.USD","LU0114720955.EUR","LU1868836591.USD","SGXZ51526630.SGD","LU0158827781.USD","LU1804176565.USD","LU2242652126.USD","LU2264538146.SGD","LU2237443622.USD","SGXZ31699556.SGD","LU2471134523.USD","LU0094547139.USD","LU0306807586.USD","LU2089283258.USD","LU1979441026.SGD","PFE","XLV","LU0354030511.USD","LU2491050071.SGD","LU0943347566.SGD","VHT","LU0985481810.HKD","BK4534","ELIL","IE00BN29S564.USD","LU0225284248.USD","LU1917777945.USD","SG9999002224.SGD","LU2211815571.USD","LU0823434740.USD","BK7067","HRTS","IE00B19Z3B42.SGD","PPH","LU2168564149.EUR","LU0316494557.USD","LU2237443549.SGD","LU2596442595.SGD","LU1127390331.HKD","LU0345770993.USD","LU1988902786.USD","IE00BKDWB100.SGD","LU0174119429.USD","LU0256863902.USD","LU2108987350.USD","LU0354030438.USD","LU0820562030.AUD","LU2462157665.USD","IE0005OL40V9.USD","LU0345770308.USD","LU0109394709.USD","LU1267930730.SGD","LU0109391861.USD","LU0306806265.USD","BK4588","AGNG","LU0683600562.USD","IE00B775H168.HKD","IE00BLSP4452.SGD","IBB","IE00BJLML261.HKD","LU1551013342.USD","LLY","AMGN","BK4007","LU0289739699.SGD","LU1894683348.USD","LU0456855351.SGD","LU2361045086.USD","SG9999018857.SGD","LU0122379950.USD","LU1623119135.USD","IHE","GDOC","LU2023251221.USD","IE00BKPKM429.USD","LU2357305700.SGD","LU2461242641.AUD","LU2491050154.USD","LU2552382215.SGD","SGXZ81514606.USD","TBXU","IE00B19Z3581.USD","LU1066053197.SGD","LU1232071149.USD","LU2750360997.AUD","IE00BFTCPJ56.SGD","LU2237443895.HKD","IE0001KFT4U8.USD","IE00BK4W5L77.USD","LU0471298694.HKD","JDOC","LU2168564495.EUR","LU1894683264.USD","LU1720051108.HKD","SG9999014898.SGD","LU2237443382.USD","IE00BFSS7M15.SGD","IE00BK4W5M84.HKD","LU0238689110.USD","BIB","LU2087625088.SGD","LU0096364046.USD","LU2237443465.HKD","LU2237443978.SGD","LU0640476718.USD","WDNA","FTXH","LU2756315318.SGD","LU0882574055.USD","IE00B1BXHZ80.USD","LU1323610961.USD","BK4592","LU2471134879.HKD","TRUH","LU0058720904.USD","MEDX","LU1551013425.SGD","LU1629891620.HKD"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":13,"code":"91000000","status":"200"}]}}